Aston Sci.

Aston Sci. is a clinical-stage biopharmaceutical company founded in 2018, headquartered in Korea South. The company's slogan, "Empowering Patients with Innovative Cancer Immunotherapy," aligns with its focus on developing innovative medicines in oncology, immunology, and geriatrics. This includes therapeutic cancer vaccines and proteostasis modulators. Aston Sci.'s last investment was a significant KRW27.00B Series C round on 12 January 2021, with participation from prominent investors such as Mirae Asset, Mirae Asset Venture Investment, Timefolio Asset Management, Lakewood Partners, and Gen-tech Investments. The company's mission to prioritize human well-being positions it as a compelling player in the Biotechnology and Pharmaceutical industries. With its innovative approach to cancer immunotherapy, Aston Sci. presents a promising opportunity for venture capital consideration.